MedTrace Logo

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

NCT00222469 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-07-09

No results posted yet for this study

Summary

The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.

In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin, and gemcitabine together.

Conditions

Interventions

DRUG

bevacizumab

10mg/kg IV on Day 1 Q 2 weeks

DRUG

gemcitabine

1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.

DRUG

oxaliplatin

100mg/m2 on Day 2 and Q 2 weeks.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Mehrdad Jafari, MD, PhD · University of Oklahoma

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222469 on ClinicalTrials.gov